Skip to content

Prevalence and Genetic Alternation of Autoimmune Polyglandular Syndrome Type II in Taiwan

Prevalence and Genetic Alternation of Autoimmune Polyglandular Syndrome Type II in Taiwan

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05578105
Enrollment
650
Registered
2022-10-13
Start date
2022-01-01
Completion date
2026-12-31
Last updated
2022-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune Polyendocrine Syndrome Type II

Brief summary

Autoimmune polyendocrine syndrome (APS) is an autoimmune disease involving at least two endocrine organ. It is classified into type I and type II diseases. Among them, APS type II is more common. It is diagnosed when two of the three following diseases are diagnosed in the same patient, including type 1 diabetes mellitus, autoimmune thyroid disease, and primary adrenal insufficiency. In this study, we will observe the epidemiology, clinical characteristics, and genetic variants of APS II in Taiwan.

Interventions

OTHERno intervention

No intervention, only observation

Sponsors

National Taiwan University Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients visited NTUH during 2006-2021, and had at least two of the three diseases: type 1 DM, primary adrenal insufficiency, and autoimmune thyroid disease.

Exclusion criteria

* Patients aged less than 20 years old

Design outcomes

Primary

MeasureTime frameDescription
Rates of endocrine organs involved2022/1/1 ~ 2026/12/31We will observe the rate of each endocrine organ involved, including adrenal gland, thyroid, and pancreas

Countries

Taiwan

Contacts

Primary ContactShyang-Rong Shih, MD, PhD
srshih@ntu.edu.tw+886-972653337

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026